Canaccord initiates Maze Therapeutics stock rating at Buy on kidney drug potential
Covered in this story
What has happened since
- Maze Therapeutics Inc is up 7.6% since this was published, 3 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $MAZE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Maze Therapeutics Inc →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.